English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Treatment with I.C.R.F. 159 completely inhibited metastasis formation in mice implanted with Lewis lung carcinoma at doses having little influence on the rate of growth of the primary implant. This inhibition was due to the effect of I.C.R.F. 159 on the development of blood vessels of the invading margins of the primary tumour. So far as is known, this is the first time a drug has induced a specific loss of the malignant characteristic of blood-borne tumour cell dissemination.

Inhibition of Metastatic Spread by I.C.R.F. 159: Selective Deletion of a Malignant Characteristic